Srini Akkaraju, Founder and Managing General Partner of Samsara BioCapital. See sector focus and contact routes.
Srini Akkaraju, Founder and Managing General Partner of Samsara BioCapital, invests across the full biotech lifecycle—from seed-stage company creation to late-stage financings and public positions—primarily in human therapeutics like oncology, immunology, and gene therapy[1][3]. His distinctive thesis emphasizes a patient-first, long-term, company-building approach that translates cutting-edge biology into novel medicines for unmet medical needs, leveraging his MD/PhD background in immunology from Stanford[2][3]. While specific check sizes for Akkaraju individually are not detailed, Samsara’s typical investment range is $10M–$100M with a sweet spot of $25M[6]. Notable portfolio companies include Nkarta Therapeutics, Ionpath, Delfi Diagnostics, Enara Bio, and Scholar Rock Holding Corp, the firm’s largest public holding[7].
Every field above is read from the StartupFundraising investor directory — disclosed location, recorded investments and stated focus — and re-checked as filings arrive. Founders pair it with investors in Palo Alto when building a target list.
Investors like Srini Akkaraju · Full investor directory · Investor access · Company funding database